EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nationwide implementation and evaluation of the Tumor‐First workflow for genetic testing in ovarian carcinoma

Vera M Witjes iD, Joanne A de Hullu iD, Dorien M A Hermkens, Yvonne H C M Smolders, Julie E M Swillens iD, Sarah-Lotte Slob, Tjalling Bosse, Marian J E Mourits, Margreet G E M Ausems, Tumor‐First Implementation Group, Marjolijn J L Ligtenberg iD, Nicoline Hoogerbrugge

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Vera M Witjes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Genetic Testing, Ovarian Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite international agreement on the importance of tumor DNA testing and germline testing for determining PARP inhibitor treatment eligibility in patients with ovarian carcinoma (OC) and for cancer prevention in their relatives, the optimal strategy remains under debate. In the Netherlands, the “Tumor‐First workflow” was initiated and implemented nationwide: a well‐validated tumor DNA test is the primary test for detecting tumor pathogenic variants (PVs) in OC risk genes ( BRCA1/2, RAD51C/D, BRIP1, PALB2 ). The detection of tumor PVs is subsequently used to stratify germline testing and determine treatment eligibility. The Tumor‐First workflow is efficient and saves costs. The aim of this study was to evaluate the nationwide implementation of the Tumor‐First workflow. We analyzed real‐time genetic testing practices, including tumor DNA and germline testing, in patients diagnosed with OC from 2019 to 2023, as identified through the Dutch Pathology Registry (Palga). Testing data were collected from diagnostic pathology and genetic reports. Out of the 3926 OC patients, 2778 (71%) received OC tumor DNA testing as the primary test. Between 2019 and 2023, this percentage increased from 50% to 85%. Of these tumor DNA tests, 2703 (97%) were successful, with 398 (15%) resulting in the identification of a PV in an OC risk gene. Most of these patients (291; 73%) underwent germline testing, and 147 (51%) were found to have a germline PV. We conclude that the nationwide implementation of the Tumor‐First workflow for OC was effective. Multidisciplinary efforts contributed to a more efficient detection of germline and somatic PVs in OC risk genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingOvarian NeoplasmsHumansFemaleWorkflowNetherlandsMiddle AgedBRCA2 ProteinGerm-Line MutationGenetic Predisposition to DiseaseAdultAgedBRCA1 ProteinFanconi Anemia Complementation Group N ProteinPoly(ADP-ribose) Polymerase InhibitorsRNA HelicasesFanconi Anemia Complementation Group Proteins

Stichwörter der Autor:innen

BRCAepithelial ovarian cancerimplementationneoplasm DNAworkflow

Substanzen

BRCA2 ProteinBRCA2 protein, humanBRCA1 protein, humanPALB2 protein, humanBRCA1 ProteinFanconi Anemia Complementation Group N ProteinBRIP1 protein, humanPoly(ADP-ribose) Polymerase InhibitorsRNA HelicasesFanconi Anemia Complementation Group Proteins

Autor:innen und Institutionen

  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

ORCID-Profile: Vera M Witjes, Joanne A de Hullu, Julie E M Swillens, Marjolijn J L Ligtenberg

Förderung

  • KWF Kankerbestrijding

Zitieren

APA

Witjes, V. M., de Hullu, J. A., Hermkens, D. M. A., Smolders, Y. H. C. M., Swillens, J. E. M., Slob, S. L., Bosse, T., Mourits, M. J. E., Ausems, M. G. E. M., Tumor‐First Implementation Group, Ligtenberg, M. J. L., & Hoogerbrugge, N. (2025). Nationwide implementation and evaluation of the Tumor‐First workflow for genetic testing in ovarian carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.35440

Vancouver

Witjes VM, de Hullu JA, Hermkens DMA, Smolders YHCM, Swillens JEM, Slob SL, et al. Nationwide implementation and evaluation of the Tumor‐First workflow for genetic testing in ovarian carcinoma. International Journal of Cancer. 2025. doi:10.1002/ijc.35440

BibTeX
@article{Witjes2025,
  author = {Witjes, Vera M and de Hullu, Joanne A and Hermkens, Dorien M A and Smolders, Yvonne H C M and Swillens, Julie E M and Slob, Sarah-Lotte and Bosse, Tjalling and Mourits, Marian J E and Ausems, Margreet G E M and Tumor‐First Implementation Group, Tumor‐First Implementation Group and Ligtenberg, Marjolijn J L and Hoogerbrugge, Nicoline},
  title = {Nationwide implementation and evaluation of the Tumor‐First workflow for genetic testing in ovarian carcinoma},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35440}
}
Kostenlos starten →